MétaCan
Menu
Back to cohort
Record W4414050013 · doi:10.1093/dote/doaf061.052

374. ENDOSCOPIC SUBMUCOSAL DISSECTION AND ADJUVANT THERAPY FOR HIGHER STAGE ESOPHAGEAL CANCER: READY FOR PRIME TIME?

2025· article· en· W4414050013 on OpenAlexaff
Gursagar Jhanji, Aisha Mansoor Ali, Richard Liu, Stephen Gowing, Gordon Buduhan, Biniam Kidane

Bibliographic record

VenueDiseases of the Esophagus · 2025
Typearticle
Languageen
FieldMedicine
TopicEsophageal Cancer Research and Treatment
Canadian institutionsCancerCare ManitobaKelowna General HospitalResearch Institute in Oncology and HematologyUniversity of Manitoba
Fundersnot available
KeywordsEsophagectomyEsophageal cancerStage (stratigraphy)Radiation therapyNeoadjuvant therapyPopulationOccultCohortAdjuvant therapyDissection (medical)

Abstract

fetched live from OpenAlex

Abstract Background Endoscopic submucosal dissection (ESD) is acceptable for pT1a esophageal cancers. Esophagectomy is standard-of-care for higher stages, even if negative margin is achieved with endoscopic resection. This is due to risks of occult nodal disease that would otherwise go undetected and untreated. Some patients are ineligible for esophagectomy (due to prohibitive medical comorbidities) or decline it. In these patients, multi-disciplinary tumor conferences struggle to understand the optimal treatment. We aimed to assess treatment patterns and outcomes for patients undergoing ESD for ≥pT1b cancers who were ineligible for or declined esophagectomy. Methods Retrospective cohort study was performed using prospectively-collected data. Patient population included all consecutive patients who underwent ESD at a tertiary hospital with pT1b or higher disease (declined or ineligible for esophagectomy). Complications and survival outcomes are reported. Univariable analysis was performed. For comparative analysis, patients who underwent esophagectomy were identified with no neoadjuvant therapy and who had pT1b or higher disease with proven pN0. Propensity-score matching (optimal matching, without replacement) was used to compare short and long-term outcomes of matched (2:1) patients undergoing ESD and esophagectomy. Perfect matching on pT-stage was mandated. Survival analysis was performed on the matched groups. Results Fifty-three ESD patients met inclusion criteria. Mean age was 74.8 (SD = 9.4) and 81.1% male. Majority were adenocarcinoma while 15.1% were squamous cell cancers. Chemoradiation was received by 24.5% (n = 13) of patients whereas 13.2% (n = 7) received adjuvant radiation alone. Most prevalent stages were pT1bSM2 (41.5%, n = 22) and pT1bSM3 (26.4%, n = 14). Incidence of positive margins (mostly focal deep positive margin) ranged from 0 in pT1bSM1 to 70–100% in pT2/pT3. Incidence of complications was 15.1% (n = 8); most requiring endoscopic dilatation. Twenty-five esophagectomy patients (no neoadjuvant) were compared to ESD population. Two-year and five-year progression-free/overall survival were not different in propensity-matched analyses (p > 0.10). Conclusion Organ-preserving treatment with ESD and adjuvant chemoradiation/radiation is feasible and has minimal complications, with comparable survival to esophagectomy in patients with higher stage (>pT1b) esophageal cancers. This was in patients who were ineligible for or declined esophagectomy; furthermore, there is higher likelihood of undiagnosed/occult nodal disease in the ESD group as the esophagectomy group was proven to be pN0. Thus, these analyses are highly biased towards worse outcomes for the ESD group. Larger comparative trials incorporating patient-reported outcomes and quality-of-life are required. Translational work to identify better biomarkers to select patients for adjuvant therapies is needed.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.352
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueDiseases of the EsophagusSame topicEsophageal Cancer Research and TreatmentFrench-language works237,207